Pro-Dex, Inc.
NASDAQ:PDEXMedical - Instruments & Supplies
+$3.54 today
- Market cap
- $204.61M
- Beta
- -0.00
- P/E (TTM)
- 17.1
- EPS (TTM)
- $3.75
Volume 0.04M
Average 0.04M
PDEX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Pro-Dex, Inc.NASDAQ: PDEX
Research & Development · Q3 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q3 FY2026 research & development of $827K fell 12.7% year over year, behind the -9.4% change in trailing-twelve-month research & development. Sequentially, it rose 12.7% from the prior quarter. Over 3 fiscal years it compounded at +6.9% a year.
Context
- Research & development amounted to 5.5% of revenue in FY2025, down 0.5 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -12.7% toward the trailing-twelve-month pace of -9.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 3.64M USD
- Year-over-year change
- +14.0%
- 4-year CAGR
- +5.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 3.64M | +14.0% |
| FY2024 | 2024-06-30 | 3.19M | +13.7% |
| FY2023 | 2023-06-30 | 2.8M | -5.9% |
| FY2022 | 2022-06-30 | 2.98M | +0.0% |
| FY2021 | 2021-06-30 | 2.98M | — |
Research & Development vs competitors
How PDEX compares with its peers on the latest reported figures
- PDEX's LTM Mar 2026 research & development of $3.23M is the 8th highest of the 9 companies compared; the peer median is $9.49M.
- Its year-over-year change of -9.4% is the 4th highest of 9, against a peer median of -11.0%.
- Research & development amounts to 4.3% of revenue for PDEX, versus a peer median of 93.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $32.45M | -22.6% | +7.0% | — | |
| LTM Mar 2026 | $15.76M | +21.0% | +38.5% | — | |
| LTM Mar 2026 | $13.34M | -7.2% | +1.9% | 38.8% | |
| LTM Mar 2026 | $12.87M | -10.5% | -2.6% | 22573.7% | |
| LTM Mar 2026 | $6.11M | -11.4% | -6.7% | 5814.3% | |
| LTM Mar 2026 | $5.46M | -7.8% | +691.2% | 106.3% | |
| LTM Mar 2026 | $3.33M | -25.7% | -9.5% | 6.0% | |
| LTM Mar 2026 | $3.23M | -9.4% | +6.9% | 4.3% | |
| LTM Mar 2026 | $319.38K | -20.4% | -50.4% | 80.5% | |
| Peer median (excluding PDEX) | $9.49M | -11.0% | -0.4% | 93.4% | |
Competitors are the stored peer set for PDEX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 42.04M | 42.04M | 46.09M | 53.84M | 66.59M |
| Cost of Revenue | 28.91M | 28.91M | 33.34M | 39.29M | 47.08M |
| Gross Profit | 13.13M | 13.13M | 12.75M | 14.55M | 19.51M |
| Gross Margin | 31.2% | 31.2% | 27.7% | 27.0% | 29.3% |
| Research & Development | 2.98M | 2.98M | 2.8M | 3.19M | 3.64M |
| Selling, General & Admin | 4.99M | 4.99M | 4.18M | 4.19M | 5.19M |
| Operating Expenses | 8.01M | 8.01M | 6.99M | 7.38M | 8.82M |
| Depreciation & Amortization | 726K | 726K | 857K | 1.16M | 1.24M |
| EBITDA | 6.88M | 6.88M | 10.82M | 4.35M | 14.13M |
| EBITDA Margin | 16.4% | 16.4% | 23.5% | 8.1% | 21.2% |
| Operating Income | 5.12M | 5.12M | 5.76M | 7.17M | 10.69M |
| Operating Margin | 12.2% | 12.2% | 12.5% | 13.3% | 16.1% |
| Interest Income | 126K | 76K | 294K | 144K | 82K |
| Interest Expense | 352K | 464K | 533K | 558K | 829K |
| Other Income / Expenses | 571K | 571K | 3.67M | (4.54M) | 1.37M |
| Income Before Tax | 5.69M | 5.69M | 9.43M | 2.63M | 12.06M |
| Pre-Tax Margin | 13.5% | 13.5% | 20.5% | 4.9% | 18.1% |
| Income Tax Expense | 1.12M | 1.12M | 2.35M | 507K | 3.08M |
| Net Income | 4.57M | 4.57M | 7.07M | 2.13M | 8.98M |
| Net Margin | 10.9% | 10.9% | 15.3% | 4.0% | 13.5% |
| EPS (Basic) | 1.17 | 1.26 | 1.98 | 0.61 | 2.73 |
| EPS (Diluted) | 1.13 | 1.21 | 1.95 | 0.60 | 2.67 |
| Weighted Avg Shares | 3.8M | 3.64M | 3.57M | 3.5M | 3.29M |
| Weighted Avg Shares (Diluted) | 3.94M | 3.76M | 3.64M | 3.57M | 3.36M |
Pro-Dex, Inc.
NASDAQ:PDEX
Intrinsic Alpha fair value
Locked
Current Price
$63.94
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.